Tariq Enezate is a Cardiology physician. OpenAlex indexes 62 publications with 348 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2325 18th St Ste 130
Columbus, IN 472015387
Telephone
812-379-2020Provider last certified this registry record 30 Oct 2025.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20251 payment
- Edwards Lifesciences CorporationProgram year20251 payment
- CARDIVA MEDICAL, INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
79.4%Beta blocker24.2%Metoprolol Tartrate43%Metoprolol Succinate31%Carvedilol26%Part D≥45 patientsStatin17.5%Atorvastatin Calcium80%Rosuvastatin Calcium13%Pravastatin Sodium7%Part D<11 patients+ 6 more classes in this area
Blood & clotting
15.4%P2Y12 inhibitor10.2%Clopidogrel69%Brilinta31%Part D<11 patientsFactor Xa inhibitor5.2%Eliquis100%Part D≥14 patientsMetabolism & gastrointestinal
5.2%SGLT2 inhibitor5.2%Jardiance100%Part D≥18 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- AngioVac for Minimally Invasive Removal of Intravascular and Intracardiac Masses: a Systematic Review
Current Cardiology Reports
2022 - Drug-eluting versus nondrug peripheral vascular interventions
Archives of Medical Science - Atherosclerotic Diseases
2022 - Outcomes of Percutaneous Balloon Aortic Valvuloplasty in Patients Undergoing Transcatheter Aortic Valve Replacement
Cardiovascular revascularization medicine
2021 - Drug-Eluting Versus Conventional Peripheral Vascular Interventions
Cardiovascular revascularization medicine
2021 - Outcomes of concomitant percutaneous coronary interventions and transcatheter aortic valve replacement
Archives of Medical Science - Atherosclerotic Diseases
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”